ClinicalTrials.gov
public full text
Public Domain
Abrilumab (AMG 181) in Adults With Moderate to Severe Crohn's Disease
The primary objective of this study is to evaluate the efficacy of abrilumab as measured by the proportion of participants achieving Crohn's Disease Activity Index (CDAI) remission (CDAI \< 150) after treatment for 8 weeks.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Assessment of Mucosal Activity to Improve the Prognosis of Patients With Crohn's Disease Treated With Immunosuppressants#1245211
- ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1#1057376
- A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's Disease (CD)#896070
- ABTECT - Maintenance#800797
- Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease#1111695
Record · ID 1280208
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive